Voyager Therapeutics, Inc. — Q2 2016 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2016. Voyager is a clinical-stage gene therapy company developing AAV-based treatments for central nervous system diseases. It had no approved products and generated no product-sales revenue; reported revenue came from its Genzyme collaboration.
Financial highlights
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Collaboration revenue | $3.7m | $4.9m | $8.6m | $7.5m |
| Research and development expense | $10.5m | $6.5m | $19.2m | $12.0m |
| General and administrative expense | $2.9m | $2.4m | $6.4m | $4.3m |
| Operating loss | $9.6m | $4.0m | $17.1m | $8.8m |
| Net loss | $9.3m | $3.9m | $16.5m | $18.5m |
- Margins: Gross margin is not separately presented; operating expenses substantially exceeded collaboration revenue.
- Liquidity: Cash and cash equivalents were $67.0m and marketable investments were $137.0m at June 30, totaling approximately $204.0m, versus approximately $224.3m at December 31, 2015. Management expected current resources to fund its operating plan into 2019, subject to execution and spending assumptions.
- Cash flow: Six-month operating cash use was $19.2m, investing activities provided $54.8m, and financing activities provided $0.1m. Cash increased $35.7m, primarily reflecting maturities of marketable securities and cash reallocation.
- Debt and obligations: The filing reports no debt balance. Total liabilities were $54.1m, including $47.2m of deferred collaboration revenue. Operating lease commitments totaled $30.4m through 2024.
Changes versus comparable periods
- Q2 collaboration revenue fell $1.2m year over year. Voyager extended the estimated service periods for two Genzyme-related accounting units, reducing Q2 recognized revenue by $1.2m.
- Six-month collaboration revenue rose $1.1m year over year, while six-month R&D expense increased $7.2m and G&A expense increased $2.1m, reflecting expanded research activity, staffing, facilities, and public-company costs.
- Q2 net loss widened by $5.4m year over year. The six-month net loss was lower by $1.9m, largely because the 2015 period included $9.8m of expense from remeasurement of preferred-stock tranche rights.
- Year-over-year per-share loss comparisons are affected by the November 2015 IPO and conversion of preferred stock into common shares.
Outlook, risks, and notable items
- Management targeted human proof-of-concept data from the Phase 1b VY-AADC01 advanced Parkinson’s disease trial in Q4 2016, and expected to submit an IND for its ALS program in late 2017. These are forward-looking targets, not assured outcomes.
- Voyager reported seven CNS programs, including Parkinson’s disease, ALS, Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy, frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
- The Genzyme agreement includes potential milestone payments of up to $645m across programs and tiered royalties, but payments depend on option exercises, development, regulatory approvals, and commercial performance. The company remains responsible for substantial pre-option development costs.
- Management expects significant operating losses and rising R&D spending to continue. Clinical, regulatory, manufacturing, intellectual-property, commercialization, and financing outcomes remain uncertain; additional funding may be needed and may not be available on acceptable terms.
- A new lease and lease extension increased future facility commitments; additional Cambridge space was projected to be ready for occupancy in early 2017. The filing reported no litigation and no off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, safety, enrollment, and timing of the VY-AADC01 Phase 1b trial and the planned Q4 2016 proof-of-concept data.
- Whether the ALS IND target and other program milestones remain on schedule, and the development costs required to reach them.
- Cash burn, investment balances, and whether the stated runway into 2019 remains valid as expenses and lease costs rise.
- Genzyme option decisions, collaboration revenue recognition estimates, and the conditions attached to potential milestones and royalties.
- Manufacturing readiness, future financing needs, and the potential dilution or restrictions from any financing.